Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Downgrades Oncorus to Neutral

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.
byBenzinga Newsdesk
December 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Matthew Barcus downgrades Oncorus (NASDAQ:ONCR) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Salona Global Executes Binding Agreement to Acquire the Physical Medicine Assets of Mirion Technologies’ Biodex Medical Systems for Up to $8M

By Charles Gross
November 29, 1:36 PM
Salona Global Medical Device Corporation ("Salona Global," "SGMD," or the "Company") (TSXV:SGMD) has executed a definitive asset purchase agreement (the "Asset Purchase Agreement") to acquire the physical medicine assets (the "Acquired Assets") of Biodex Medical Systems, Inc. ("Biodex").

TSXV:SGMD